Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDS00002
Target NameMuscarinic acetylcholine receptor M1    
Type of TargetSuccessful target    
Drug Potency against TargetBenztropineIC50 = 0.294 nM[1]
EthopropazineIC50 = 257000 nM[2]
AtropineKi = 1 nM[3]
DarifenacinKi = 15.8 nM[3]
TolterodineKi = 3.98 nM[3]
PirenzepineKi = 6.3 nM[3]
OxybutyninKi = 6.3 nM[3]
GSK1034702KD = 0.1 nM[4]
1,1-diphenyl-2-(3-tropanyl)ethanolIC50 < 10 nM[5]
Tiotropium BromideIC50 = 0.22 nM[6]
SULFOARECOLINEIC50 = 1.4 nM[7]
7-Dimethylamino-3-methyl-hept-5-yn-2-oneIC50 = 101 nM[8]
N-methoxyquinuclidine-3-carboximidoyl chlorideIC50 = 1100 nM[9]
7-Pyrrolidin-1-yl-hept-5-yn-2-one oximeIC50 = 1254 nM[8]
6-Dimethylamino-2-methyl-hex-4-ynal oximeIC50 = 13230 nM[8]
7-Dimethylamino-hept-5-yn-2-one oximeIC50 = 139 nM[8]
1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dioneIC50 = 15 nM[10]
3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octaneIC50 = 16000 nM[11]
SB-202026IC50 = 170 nM[12]
2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oximeIC50 = 1928 nM[8]
N-methoxyquinuclidine-3-carboximidoyl fluorideIC50 = 2000 nM[9]
N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamideIC50 = 21.6 nM[8]
BI-1356IC50 = 295 nM[13]
BRL-55473IC50 = 470 nM[9]
ISOLOXAPINEIC50 = 49 nM[14]
CREMASTRINEIC50 = 505 nM[15]
ACECLIDINEIC50 = 510 nM[16]
ISOCLOZAPINEIC50 = 55 nM[17]
3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-oneIC50 = 5696 nM[8]
7-Dimethylamino-hept-5-yn-2-oneIC50 = 68 nM[8]
XANOMELINEIC50 = 7 nM[18]
7-Pyrrolidin-1-yl-hept-5-yn-2-oneIC50 = 7280 nM[8]
FLUMEZAPINEIC50 = 80 nM[19]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-oneKi < 1000 nM[20]
AMINOBENZTROPINEKi = 1.12 nM[21]
CARAMIPENKi = 1.21 nM[22]
1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-ureaKi = 10700 nM[23]
DIFLUOROBENZTROPINEKi = 11.6 nM[24]
Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl esterKi = 190 nM[25]
R-dimethindeneKi = 2.4 nM[26]
2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dioneKi = 30 nM[27]
FM1-10Ki = 34 nM[28]
3alpha-(bis-chloro-phenylmethoxy)tropaneKi = 40.6 nM[24]
FM1-43Ki = 44 nM[28]
Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl esterKi = 440 nM[25]
HIMBACINEKi = 48 nM[29]
GNF-PF-5618Ki = 490 nM[30]
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl esterKi = 5.6 nM[31]
RR(17)PZKi = 53.5 nM[32]
2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-oneKi = 6.7 nM[33]
Bo(15)PZKi = 69.7 nM[32]
Action against Disease ModelPirenzepineAffinity for the muscarinic receptors in the cerebral cortex IC50: 14 nM[34]
TrihexyphenidylAffinity for the muscarinic receptors in the cerebral cortex IC50: 3.7 nM[34]
DicyclomineAffinity for the muscarinic receptors in the cerebral cortex(rat) IC50: 5.1 nM[34]
GlycopyrrolateIC50 of EFS-induced contraction in Guinea pig/h uMan trachea: 0.15 nM/0.44 nM[35]
Ref 1J Pharmacol Exp Ther. 2004 May;309(2):650-60. Epub 2004 Jan 30.Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. To Reference
Ref 2Comp Biochem Physiol B Biochem Mol Biol. 2008 Mar;149(3):401-9. Epub 2007 Nov 9.Acetylcholinesterase in the sea urchin Lytechinus variegatus: characterization and developmental expression in larvae. To Reference
Ref 3Trends Pharmacol Sci. 2001 Aug;22(8):409-14.Therapeutic opportunities from muscarinic receptor research. To Reference
Ref 4Mini Rev Med Chem. 2007 Jan;7(1):79-86.Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor. To Reference
Ref 5Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. Epub 2009 Jul 8.Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD. To Reference
Ref 6J Med Chem. 2009 Aug 27;52(16):5076-92.Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). To Reference
Ref 7J Med Chem. 1988 Jul;31(7):1312-6.Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. To Reference
Ref 8Bioorg. Med. Chem. Lett. 2(8):803-808 (1992) To Reference
Ref 9Bioorg. Med. Chem. Lett. 2(8):791-796 (1992) To Reference
Ref 10J Med Chem. 1989 May;32(5):1057-62.Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. To Reference
Ref 11J Med Chem. 1992 Apr 3;35(7):1280-90.Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. To Reference
Ref 12J Med Chem. 1997 Dec 19;40(26):4265-80.Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. To Reference
Ref 13J Med Chem. 2007 Dec 27;50(26):6450-3. Epub 2007 Dec 1.8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. To Reference
Ref 14J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. To Reference
Ref 15J Nat Prod. 2005 Apr;68(4):572-3.Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. To Reference
Ref 16J Med Chem. 1993 Apr 2;36(7):842-7.Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. To Reference
Ref 17J Med Chem. 1990 Feb;33(2):809-14.Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. To Reference
Ref 18J Med Chem. 1992 Oct 30;35(22):4011-9.Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore. To Reference
Ref 19J Med Chem. 1989 Dec;32(12):2573-82.Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. To Reference
Ref 20J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference
Ref 21J Med Chem. 1997 Mar 14;40(6):851-7.3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. To Reference
Ref 22J Med Chem. 1991 Oct;34(10):2984-9.Muscarinic receptor binding profile of para-substituted caramiphen analogues. To Reference
Ref 23J Med Chem. 1992 Aug 21;35(17):3270-9.Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. To Reference
Ref 24J Med Chem. 2006 Oct 19;49(21):6391-9.Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation. To Reference
Ref 25J Med Chem. 2000 Jun 29;43(13):2514-22.6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. To Reference
Ref 26J Med Chem. 2009 Sep 10;52(17):5307-10.Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. To Reference
Ref 27Bioorg. Med. Chem. Lett. 7(8):979-984 (1997) To Reference
Ref 28Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. Epub 2007 Nov 17.Design and synthesis of a fluorescent muscarinic antagonist. To Reference
Ref 29Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. To Reference
Ref 30J Nat Prod. 2005 Jul;68(7):1061-5.Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. To Reference
Ref 31J Med Chem. 1998 Jun 4;41(12):2047-55.6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. To Reference
Ref 32J Med Chem. 2005 Dec 1;48(24):7847-59.On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. To Reference
Ref 33J Med Chem. 1998 Oct 22;41(22):4181-5.Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. To Reference
Ref 34Br J Pharmacol. 1986 Sep;89(1):83-90.Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. To Reference
Ref 35Br J Pharmacol. 1999 May;127(2):413-20.Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543